J&J Sets Erleada On Real-Time Pathway For Castration-Sensitive Prostate Cancer Claim
Executive Summary
Erleada is ninth product known to be using US FDA’s Real-Time Oncology Review pilot program, as shown in our comprehensive chart.
You may also be interested in...
J&J's Erleada Approved By FDA In New Prostate Cancer Indication
Erleada was approved for treatment of metastatic castration-sensitive prostate cancer (mCSPC), strengthening its position versus generic Zytiga and Pfizer/Astellas's Xtandi.
Keeping Track: US FDA Greenlights Two More Novel Drugs, But Smacks Down Golodirsen
The latest drug development news and highlights from our US FDA Performance Tracker.
Real-Time Oncology Review Quickly Grows Popular; Venclexta Is Latest To Join Pilot
Genentech/AbbVie drug becomes the seventh product known to be pilot-testing US FDA's new pathway; our infographic details the program's goals and how it has been used so far for more efficient reviews of supplemental oncology indications.